Juniper appoints Alicia Secor president and CEO
Ms. Secor will also be appointed to the Board of Directors. Ms. Secor' brings more than 25 years' of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialization, and global expansion across several therapeutic areas.
She joins Juniper from Zafgen, Inc., where she served as Chief Commercial Officer and played a key role in advancing the company to a Phase 3 pre-commercialization status.
Previously Ms. Secor served 15 years at Genzyme Corporation in diverse leadership roles, most recently as the Global General Manager for the Metabolic Disease Business.
Prior to Genzyme, Ms. Secor held positions at Alkermes in business development, at Centocor (a Johnson & Johnson Company) in clinical and commercial operations. She began her career at Pfizer as a hospital-based sales representative.
Ms. Secor received an M.B.A. from Northeastern University, and a B.S. in Healthcare Administration from the University of New Hampshire.
Ms. Secor succeeds Frank Condella, who announced his intent to retire as Juniper's President and CEO earlier this year.
Mr. Condella will remain on the Board as a non-executive director, and will consult to the Company for an interim period to ensure an orderly transition. ■
What to read next
LATEST MOVES FROM Massachusetts
- BayCoast Bank appoints Matthew Flanagan as vice president
- Endurance International Group appoints Marc Montagner as interim COO
- AVEO Oncology appoints Matthew Dallas as CFO
- Radius Health appoints Jose Pepe Carmona as CFO
- Axcella appoints Ivana Magovcevic-Liebisch as vice president
More inside POST
Dean Foods Q1 loss $9.76 million Earnings